This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Catalyst (CPRX) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Catalyst (CPRX) will provide updates on earnings and revenues when its releases third-quarter 2020 results.
Ascendis Progresses With Hypoparathyroidism Drug TransCon PTH
by Zacks Equity Research
Ascendis Pharma (ASND) reports encouraging preliminary data on its hypoparathyroidism candidate, TransCon PTH. A late-stage study is anticipated to begin soon.
BioMarin (BMRN) Files NDA for Vosoritide to Treat Dwarfism
by Zacks Equity Research
BioMarin's (BMRN) BLA for vosoritide is based on final data from a phase III study, long-term data from the ongoing phase II and phase III extension studies and extensive natural history data.
BioMarin's MAA for Dwarfism Candidate Gets EMA Validation
by Zacks Equity Research
The EMA sanctions BioMarin's (BMRN) marketing authorization application for vosoritide to treat children with achondroplasia, the most common type of dwarfism.
Ascendis' Dwarfism Candidate Gets Orphan Drug Status in EU
by Zacks Equity Research
Ascendis' (ASND) TransCon CNP receives an Orphan Drug tag in Europe for the treatment of achondroplasia, the most common type of dwarfism.
Ascendis Submits BLA to FDA for TransConhGH in Pediatric GHD
by Zacks Equity Research
Ascendis Pharma (ASND) submits BLA to the FDA for TransConhGH for the treatment of pediatric growth hormone deficiency.
Biomarin to File Regulatory Applications for Vosoritide in Q3
by Zacks Equity Research
BioMarin (BMRN) plans to file regulatory applications seeking approval for its achondroplasia candidate, vosoritide, in the third quarter of 2020.
BlackBerry (BB) to Report Q4 Earnings: What's in the Offing?
by Zacks Equity Research
BlackBerry's (BB) fiscal fourth-quarter performance is likely to have benefited from its investment in product development and go-to-market strategy.
What's in Store for Science Applications' (SAIC) Q4 Earnings?
by Zacks Equity Research
Science Applications' (SAIC) fourth-quarter fiscal 2020 results are likely to reflect gains from new business wins and the Engility acquisition.
Ascendis Pharma (ASND): Strong Industry, Solid Earnings Estimate Revisions
by Zacks Equity Research
Ascendis Pharma (ASND) has seen solid estimate revision activity over the past month, and belongs to a strong industry as well.
Ascendis Pharma A/S (ASND) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Ascendis Pharma A/S (ASND) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Alkermes (ALKS) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
We expect Alkermes (ALKS) to provide revenue updates on its proprietary marketed products and pipeline candidates when it releases fourth-quarter earnings on Feb 13.
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis Inc. (ZTS) will provide financial numbers for fourth-quarter 2019 and pipeline updates on Feb 13.
Emmaus (EMMA) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors look forward to updates on key drug Endari's expansion plans when Emmaus (EMMA) releases fourth-quarter 2019 results.
Top Ranked Momentum Stocks to Buy for November 21st
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 21st
Top Ranked Momentum Stocks to Buy for November 18th
by Zacks Equity Research
Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, November 18th
What's in Store for Helmerich & Payne (HP) in Q4 Earnings?
by Zacks Equity Research
Helmerich & Payne's (HP) much popular technologically-advanced FlexRigs with strong daily rate margins might reflect on segmental profits in the to-be-reported results.
5 Biotech Stocks Set to Beat Q3 Earnings Estimates
by Kinjel Shah
Here we highlight five biotech companies, which are expected to deliver positive earnings surprises in this earnings season.
CannTrust (CTST) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
On CannTrust's (CTST) third-quarter earnings call, investor focus will be on the company's efforts to regain licenses for producing and selling cannabis.
Zoetis (ZTS) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Zoetis (ZTS) is expected to provide pipeline updates during the third-quarter earnings call.
Ascendis Pharma A/S (ASND) Upgraded to Buy: Here's Why
by Zacks Equity Research
Ascendis Pharma A/S (ASND) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Ascendis Pivotal Growth Hormone Deficiency Study Data Positive
by Zacks Equity Research
Ascendis Pharma's (ASND) growth hormone deficiency candidate fares better than Pfizer's Genotropin in improving annual rate for increase in height in children.
What Makes Ascendis Pharma A/S (ASND) a New Buy Stock
by Zacks Equity Research
Ascendis Pharma A/S (ASND) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Company News For Mar 5, 2019
by Zacks Equity Research
Companies in the news are; PLCE, BIIB, NITE, ASND and TAK
Ascendis Pharma Files IND for Hypoparathyroidism Candidate
by Zacks Equity Research
Ascendis Pharma (ASND) submits regulatory application to initiate a phase II study in the United States on its hypoparathyroidism therapy candidate, TransCon PTH.